Russia's new cancer vaccine shows promise after successful preclinical trials, targeting colorectal cancer and more.

Russia's new cancer vaccine, developed by the Federal Medical and Biological Agency, has successfully completed preclinical trials, showing high safety and efficacy. The vaccine is now ready for use, pending official approval, and initially targets colorectal cancer, with promising results also seen for glioblastoma and melanoma. This development marks a significant step in cancer research and treatment.